USE OF RITUXIMAB IN PATIENTS WITH SYSTEMIC MANIFESTATIONS OF PRIMARY SJOGREN'S SYNDROME

The data on the efficacy of rituximab (RTM) in systemic manifestations of primary Sjogren's syndrome (PSS) are limited by single trials.Objective: to evaluate the efficacy of RTM in patients with the systemic manifestations of PSS.Subjects and methods. RTM therapy was performed in 24 patients w...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: O. A. Logvinenko, V. I. Vasilyev, T. N. Safonova, E. B. Rodionova, E. N. Aleksandrova
Médium: Artigo
Jazyk:Russo
Vydáno: IMA-PRESS LLC 2014-12-01
Edice:Научно-практическая ревматология
Témata:
rituximab
primary sjogren's syndrome
cryoglobulinemic vasculitis
On-line přístup:https://rsp.mediar-press.net/rsp/article/view/2006
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky